| Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly | 09/26 16:05 | globenewswire.com |
| Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 09/10 16:40 | globenewswire.com |
| Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences | 08/29 16:05 | globenewswire.com |
| Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 08/12 16:05 | globenewswire.com |
| Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2024 Earnings Call Transcript | 08/08 21:23 | seekingalpha.com |
| Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates | 08/08 19:01 | zacks.com |
| Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges | 08/08 08:30 | globenewswire.com |
| Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release | 08/01 11:06 | zacks.com |
| Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 | 07/18 16:05 | globenewswire.com |
| Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 07/10 19:29 | globenewswire.com |